X4 Pharmaceuticals Inc XFOR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $2.90
- Day Range
- $2.82–2.95
- 52-Week Range
- $2.80–4.83
- Bid/Ask
- $2.78 / $2.95
- Shares Outstanding
- 99.15M
- Market Cap
- $280.59M
- Volume/Avg
- 501,492 / 835,788
Key Statistics
- Price/Earnings (Normalized)
- 27.07
- Price/Sales
- 18.20
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 45
- Website
- https://www.x4pharma.com
Valuation
|
Metric
|
XFOR
|
|---|---|
Price/Earnings (Normalized) | 27.07 |
Price/Book Value | 1.75 |
Price/Sales | 18.20 |
Price/Cash Flow | — |
Price/Earnings
XFOR
Financial Strength
|
Metric
|
XFOR
|
|---|---|
Quick Ratio | 10.84 |
Current Ratio | 11.30 |
Interest Coverage | −10.11 |
Quick Ratio
XFOR
Profitability
|
Metric
|
XFOR
|
|---|---|
Return on Assets (Normalized) | −37.65% |
Return on Equity (Normalized) | −70.79% |
Return on Invested Capital (Normalized) | −41.41% |
Return on Assets
XFOR
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|PzL?>^ | LOCK|^Yh@ | $128B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|%x^t^k | LOCK|&%^$x | $76B | |||
| Moderna Inc
MRNA
| LOCK|n@xJDPd | LOCK|<&& | $75B | |||
| argenx SE ADR
ARGX
| LOCK|z>VPY^c | LOCK|Zqk | $60B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|s%$pZG< | LOCK|%!Q | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|^Nq&gpR | LOCK|D!>Q | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|dV%$>&l@ | LOCK|tcdl | $26B | |||
| BioNTech SE ADR
BNTX
| LOCK|kP!>!p | LOCK|cj | $24B | |||
| Incyte Corp
INCY
| LOCK|M@dtHV | LOCK|b$^ | $24B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|$@?BWM | LOCK|<^h | $15B |
United States